Leukemia Research Foundation News

Blina may be effective in first-line treatment of Pediatric B-ALL

Blinatumomab, or Blina, appears to be a safe and effective first-line treatment option for young patients with B-cell acute lymphoblastic leukemia (B-ALL) who don’t tolerate chemotherapy, according to a study recently published in the Journal of Clinical Oncology.

Chemotherapy treatments can have a negative impact on a child’s quality of life. This study looked at the possibility that Blina could be a less toxic first step in treatment for some patients.

From February 2018 to February 2023, 105 patients were followed.

After analysis, researchers concluded that Blina is safe and effective in first-line treatment of chemotherapy-intolerant children and young persons with ALL.

Read full article here.


FDA Approves Iclusig Plus Chemo for Ph+ ALL

Pre-transplant gut microbiome may influence likelihood of GVHD

New findings may help donor cells survive AML immunotherapy treatment